NCT02334449View on ClinicalTrials.gov

First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

LML134

LML134 will be administered first as single doses and then as multiple doses

DRUG

Placebo

All study cohorts (except food effect cohort) are placebo controlled

Trial Locations (1)

14050

Novartis Investigative Site, Berlin

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY